Hemlibra® ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 288 | Autoimmune acquired coagulation factor deficiency | 2 |
288. Autoimmune acquired coagulation factor deficiency
Clinical trials : 205 / Drugs : 238 - (DrugBank : 31) / Drug target genes : 18 - Drug target pathways : 26
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-004430-42-AT (EUCTR) | 22/06/2021 | 22/04/2021 | Evaluation of the effect of emicizumab in patients suffering from acute bleeds with previously no family history. | Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial | Acquired Hemophilia A (AHA) MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acquired hemophilia with anti FVIII, XI, or XIII;System Organ Class: 100000004851 MedDRA version: 20.0;Classification code 10053760;Term: Acquired hemophilia;System Organ Class: 100000004851;Therapeutic area: Body processes [G] - Immune system processes [G12] | Trade Name: Hemlibra® INN or Proposed INN: Emicizumab Other descriptive name: RO5534262 EMICIZUMAB | GWT-TUD GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 47 | Phase 2 | Austria;Germany | ||
| 2 | EUCTR2019-004430-42-DE (EUCTR) | 25/01/2021 | 20/11/2020 | Evaluation of the effect of emicizumab in patients suffering from acute bleeds with previously no family history. | Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial | Acquired Hemophilia A (AHA) MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acquired hemophilia with anti FVIII, XI, or XIII;System Organ Class: 100000004851 MedDRA version: 20.0;Classification code 10053760;Term: Acquired hemophilia;System Organ Class: 100000004851;Therapeutic area: Body processes [G] - Immune system processes [G12] | Trade Name: Hemlibra® INN or Proposed INN: Emicizumab Other descriptive name: RO5534262 EMICIZUMAB | GWT-TUD GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 47 | Phase 2 | Austria;Germany |